MedTrace Logo

Effect Of DAAs For Treatment Of HCV On Normal Kidney

NCT03296930 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-09-29

No results posted yet for this study

Summary

The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.

Conditions

  • Antiviral Drug Adverse Reaction

Interventions

DRUG

Sofosbuvir 400 MG Oral Tablet,

Interferon free direct acting antiviral drugs used for treatment of HCV.

DRUG

Ombitasvir/paritaprevir/ritonavir

Interferon free direct acting antiviral drugs used for treatment of HCV.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Zainelabdeen A Sayed, MD · Assistant Professor of Internal Medicine

  • Mohammed M Abdallah, MD · Professor of Internal Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2018-09-30
Completion
2018-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296930 on ClinicalTrials.gov